Brepocitinib, a dual tyrosine kinase 2 and JAK1 inhibitor, is currently being evaluated in phase III clinical trials for adults with DM and is poised to be the first JAK inhibitor approved for DM.7 The gene discussed is TYK2; the disease is dermatomyositis.